Teva Pharmaceutical Industries reported a better than expected increase in second-quarter profit on Wednesday, helped by a 26 ...

Teva’s chief drug Austedo—approved in Huntington’s disease and tardive dyskinesia—grew sales 19% to $498 million for the ...